source
- FDA approves Vera Therapeutics' Trutakna for IgA nephropathy, pricing set at $425,000 per yearThe U.S. Food and Drug Administration has granted approval to Trutakna, a new therapy from Vera Therapeutics, for the treatment of IgA nephropathy. IgA nephropathy is a kidney disorder where immun…
- HHS pushes FDA to formalize public release of rejection letters to drug makersHHS announced it is preparing a new FDA regulation that would codify the agency's practice of publishing complete response letters (CRLs) that inform pharmaceutical companies of a drug's rejection.…